CoverageForm 410-K10-Q8-K13D13G13F

NRC · National Research Corp - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · NRC

Income Statement

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Revenue$34.80M-$34.61M$34.04M$33.55M-$35.82M$35.02M$35.31M-
Cost of Revenue----------
Gross Profit----------
R&D----------
SG&A$13.42M-$12.27M$17.73M$10.36M-$10.99M$11.22M$11.25M-
Total Operating Expenses$29.23M-$26.87M$32.45M$24.95M-$27.84M$26.16M$26.55M-
D&A$2.17M-$2.19M$1.74M$1.54M-$1.55M$1.51M$1.45M-
Operating Income$5.57M-$7.74M$1.59M$8.60M-$7.98M$8.87M$8.76M-
Interest Expense$1.25M-$1.46M$1.03M$899.0K-$160.0K$192.0K$605.0K-
Income Tax$1.16M-$2.15M$687.0K$1.94M-$1.61M$2.15M$1.83M-
Net Income$3.09M-$3.99M($190.0K)$5.79M-$5.69M$6.17M$6.36M-
EPS - Basic$0.14-$0.18($0.01)$0.25-$0.24$0.26$0.27-
EPS - Diluted$0.14-$0.18($0.01)$0.25-$0.24$0.26$0.27-

Balance Sheet

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Cash & Equivalents$2.55M$4.14M$2.22M$5.27M$2.50M$4.23M$3.46M$485.0K$1.70M$6.65M
Accounts Receivable$10.83M$11.11M$12.75M$12.42M$11.33M$11.05M$11.06M$10.06M$11.13M$12.38M
Inventory----------
Accounts Payable$2.23M$1.17M$1.09M$1.18M$2.03M$1.19M$2.59M$1.24M$2.40M$1.30M
Current Assets$19.98M$20.21M$20.40M$25.32M$20.40M$19.60M$20.70M$16.95M$20.01M$24.36M
Total Assets$134.56M$134.88M$135.72M$141.39M$135.18M$132.54M$131.80M$119.10M$120.91M$122.44M
Current Liabilities$38.47M$36.62M$38.57M$35.93M$37.77M$35.86M$44.28M$45.73M$48.85M$36.20M
Long-term Debt$74.02M$75.02M$76.03M$77.03M$58.67M$57.90M$44.91M$25.66M$27.57M$36.79M
Total Liabilities$121.06M$120.89M$121.41M$120.06M$105.50M$101.25M$97.17M$78.90M$83.97M$73.48M
Stockholders' Equity$13.49M$13.99M$14.31M$21.33M$29.67M$31.28M$34.62M$40.20M$36.95M$48.95M
Retained Earnings($17.68M)($17.30M)($15.47M)($16.89M)($14.01M)($17.06M)($20.86M)($23.73M)($27.04M)($30.53M)

Cash Flow

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Operating Cash Flow$7.18M---$6.65M---$12.04M-
Investing Cash Flow($1.83M)---($2.99M)---($4.14M)-
Financing Cash Flow($6.94M)---($5.39M)---($12.85M)-
CapEx$1.83M---$2.99M---$4.14M-
Free Cash Flow$5.35M---$3.66M---$7.90M-

Ratios

MetricQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Profitability
Gross margin----------
Operating margin16.0%-22.4%4.7%25.6%-22.3%25.3%24.8%-
EBITDA margin22.2%-28.7%9.8%30.2%-26.6%29.6%28.9%-
Net margin8.9%-11.5%-0.6%17.2%-15.9%17.6%18.0%-
Free cash flow margin15.4%---10.9%---22.4%-
FCF / Net income1.73---0.63---1.24-
R&D / Revenue----------
SG&A / Revenue38.6%-35.5%52.1%30.9%-30.7%32.0%31.9%-
Effective tax rate27.2%-35.0%138.2%25.1%-22.0%25.8%22.4%-
Return on assets2.3%-2.9%-0.1%4.3%-4.3%5.2%5.3%-
Return on equity22.9%-27.9%-0.9%19.5%-16.4%15.4%17.2%-
Return on invested capital4.6%-5.6%0.8%7.3%-7.8%10.0%10.5%-
Liquidity
Current ratio0.520.550.530.700.540.550.470.370.410.67
Quick ratio0.520.550.530.700.540.550.470.370.410.67
Cash ratio0.070.110.060.150.070.120.080.010.030.18
Leverage
Debt / Equity5.485.365.313.611.981.851.300.640.750.75
Debt / Assets0.550.560.560.540.430.440.340.220.230.30
Debt / EBITDA9.57-7.6523.135.79-4.712.472.70-
Interest coverage4.4x-5.3x1.5x9.6x-49.9x46.2x14.5x-
Equity multiplier9.979.649.486.634.564.243.812.963.272.50
Liabilities / Assets0.900.900.890.850.780.760.740.660.690.60
Efficiency
Asset turnover0.26-0.250.240.25-0.270.290.29-
Inventory turnover----------
Days sales outstanding114d-134d133d123d-113d105d115d-
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E121.3x-71.0x-51.2x-95.3x88.3x146.7x-
P / B27.6x-19.8x17.8x9.9x-15.7x13.7x25.7x-
P / S10.7x-8.2x11.2x8.8x-15.2x15.7x26.9x-
EV / EBITDA57.3x-35.9x135.9x34.5x-61.3x55.3x95.5x-
Growth
Revenue growth (YoY)3.7%--3.4%-2.8%-5.0%--5.6%-3.2%-3.2%-
Revenue CAGR (3y)-1.6%--2.8%-3.0%-4.4%--1.7%-1.3%-0.1%-
Revenue CAGR (5y)-0.4%-1.3%1.8%-0.2%-----
Gross profit growth (YoY)----------
Operating income growth (YoY)-35.2%--3.0%-82.1%-1.9%--19.8%-5.3%-2.8%-
Net income growth (YoY)-46.6%--29.8%--9.0%--27.8%-15.1%-8.6%-
EPS growth (YoY)-44.0%--25.0%--7.4%--25.0%-10.3%-3.6%-
EPS CAGR (3y)-20.6%--18.3%--9.7%--14.2%-9.4%-9.1%-
EPS CAGR (5y)-17.2%--13.4%--11.5%--5.0%-2.2%-3.3%-
FCF growth (YoY)46.1%----53.7%---73.5%-
FCF CAGR (5y)-16.5%----5.8%---5.1%-
Book value growth (YoY)-54.5%-55.3%-58.7%-46.9%-19.7%-36.1%-40.2%-48.3%-50.5%-32.0%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2025-12-31.

Product / service

$137.39M total
Subscription Services$125.62M · 91.4%
Service$5.72M · 4.2%
Fixed Non Subscription Services$5.37M · 3.9%
Unit Price Services$673.0K · 0.5%

Peer comparison

Same SIC group: Services-Commercial Physical & Biological Research

CompanyRevenue (last FY)Net marginROE
INCY$5.14B25.0%24.9%
CRL$4.02B-3.6%-4.6%
MEDP$2.53B17.8%98.3%
IQV$16.31B8.3%20.9%
OABI$18.67M-347.0%-24.3%

Comparing NATIONAL RESEARCH CORP against the 5 most active filers in the same SIC group.

Dividends

$0.56/share trailing 12 months · +16.7% YoY

Ex-datePer share
Mar 27, 2026$0.1600
Dec 26, 2025$0.1600
Sep 26, 2025$0.1200
Jun 27, 2025$0.1200
Mar 28, 2025$0.1200
Dec 27, 2024$0.1200
Sep 27, 2024$0.1200
Jun 28, 2024$0.1200
Mar 27, 2024$0.1200
Dec 28, 2023$0.1200
Sep 28, 2023$0.1200
Sep 15, 2023$1.0000
Jun 29, 2023$0.1200
Mar 30, 2023$0.1200
Dec 29, 2022$0.1200
Sep 29, 2022$0.2400
Jun 29, 2022$0.2400
Mar 30, 2022$0.2400
Dec 29, 2021$0.1200
Sep 29, 2021$0.1200
Jun 29, 2021$0.1200
Apr 16, 2021$0.1200
Mar 30, 2020$0.2100
Dec 30, 2019$0.2100